Cytokine release syndrome in severe COVID-19: interleukin-6 receptor antagonist tocilizumab may be the key to reduce mortality
Peking University · Peking University First Hospital · +2 more institutions
Indexed incrossrefpubmed
Abstract
No abstract available for this paper.
Citation impact
1,832
total citations
- FWCI
- 147.66
- Percentile
- 100%
- References
- 62
Citations per year
Authors
5- CZChi Zhang
Peking University, Peking University First Hospital
- ZWZhao Wu
Peking University, Peking University First Hospital
- JLJiawen Li
Peking University, Peking University First Hospital
- HZHong ZhaoCorresponding
Peking University, Peking University First Hospital, Zhejiang University
- GWGui-Qiang WangCorresponding
Peking University, Peking University First Hospital, Peking University International Hospital, Zhejiang University
Topics & keywords
Topics
Keywords
- Tocilizumab
- Cytokine storm
- Cytokine release syndrome
- Medicine
- Pneumonia
- Cytokine
- Interleukin 1 receptor antagonist
- Interleukin 6
UN Sustainable Development Goals
- Good health and well-being
No related works found for this paper.